Latest News

Thursday, October 23, 2014 | Management/Leadership , Bausch + Lomb

Bausch + Lomb Names Tony Sommer as Head of Sales for US Vision Care Division

Bausch + Lomb has named Tony Sommer head of sales for its U.S. Vision Care division. Mr. Sommer will be responsible for managing the U.S. sales function for Bausch + Lomb’s Vision Care business.…

Read the full story

Thursday, October 23, 2014 | Medical Studies

New Study Forecasts Number of Diabetic Eye Disease Cases to Reach Nearly 11 Million by 2032

Public health agencies across the country are feeling the impact from the skyrocketing number of diabetes cases on public health programs and funding, according to a news release from Prevent Blindnes…

Read the full story

Thursday, October 23, 2014 | Miscellaneous

Santen Announces Positive Outcome of the European Decentralized Procedure for Approval of Taptiqom

Santen announced the positive outcome of the Decentralized Procedure (DCP) for Taptiqom in Europe. The announcement follows the issuance of the Final Assessment Report from the Reference Member State …

Read the full story

Thursday, October 23, 2014 | Earnings & Financials

Mylan, Abbott, Enter Amended Agreement; Will be Accretive to Mylan

On October 21, 2014, Mylan Inc., a Pennsylvania corporation, New Moon B.V., a private limited liability company organized under the laws of the Netherlands, Moon of PA Inc., a Pennsylvania corporation…

Read the full story

Thursday, October 23, 2014 | Medical Studies

New Standardized DMEK Technique Saves Eyes

A new Descemet membrane endothelial keratoplasty (DMEK) technique results in low complication rates and acceptable cell density, investigators report. "We wanted to come up with a technique that …

Read the full story

Thursday, October 23, 2014 | Medical Studies

Discovery of Special Stem Cells in the Eye Could Lead to Better Treatments for Blindness

Scientists at the University of Southampton have discovered that a region on the front surface of the eye harbours special stem cells that could treat blinding eye conditions. This part of the eye is …

Read the full story

Wednesday, October 22, 2014 | Acquisitions/Mergers

Nicox's Shareholders Approve Acquisition of Aciex Therapeutics

Nicox SA announced that its shareholders voted to approve the acquisition of Aciex Therapeutics, a private, US-based, ophthalmic development pharmaceutical company, at the General Meeting held October…

Read the full story

Wednesday, October 22, 2014 | Clinical Trials

London Eye Hospital Pharma Announces US Clinical Introduction of iolAMD

London Eye Hospital Pharma announced that it has initiated US discussions to gain clinical data for its iolAMD lens system, according to a company news release. iolAMD is a novel intraocular lens syst…

Read the full story

Wednesday, October 22, 2014 | Medical Studies

Genes Related to Pediatric Glaucoma Contribute to Future Stroke

Every year in Canada about 50,000 people suffer from a stroke caused either by the interruption of blood flow or uncontrolled bleeding in the brain. While many environmental risk factors exist, includ…

Read the full story

Wednesday, October 22, 2014 | Medical Studies

New Clinical Applications for Assessing 'Higher-Order' Visual Abnormalities

A technique developed by astronomers seeking a clear view of distant objects in space is being intensively studied as a new approach to measuring and correcting visual abnormalities. The October issue…

Read the full story

Tuesday, October 21, 2014 | Glaucoma

Ivantis Announces HYDRUS II Glaucoma Study Met Primary Endpoint In a Randomized Controlled Trial at 2 Years

Ivantis, developer of the Hydrus Microstent, announced that the international HYDRUS II trial met its primary endpoint, according to a company news release. Results of the randomized, controlled study…

Read the full story

Tuesday, October 21, 2014 | Medical Studies

A Study Commissioned by the Israeli Air Force, Using GlassesOff App, Shows Air Force Pilots Gain Significant Improvement in Visual Acuity, Image Processing Speed

GlassesOff Inc. announced that statistically significant interim results from a study commissioned by the Israeli Air Force (IAF) demonstrated significant improvements in critical visual functions of …

Read the full story

Tuesday, October 21, 2014 | Earnings & Financials , Valeant Ophthalmics

Valeant Considering Raised Bid in Battle With Allergan

Valeant Pharmaceuticals International may raise its offer for Allergan, the company said after reporting better-than-expected third-quarter earnings and raising its 2014 forecast. Managers of Laval, Q…

Read the full story

Tuesday, October 21, 2014 | Acquisitions/Mergers

AbbVie Ends Purchase of Shire on U.S. Tax Rule Changes

AbbVie Inc. and Shire Plc agreed to terminate what would have been the biggest U.S. tax inversion after AbbVie pulled its support for the deal in the wake of proposed changes to U.S. rules governing s…

Read the full story

Monday, October 20, 2014 | Product Releases

Nextech Systems and MDIntelleSys Unveil Integrated, Cloud-Based EMR and Practice Management System

Nextech Systems announced the launch of its integrated ophthalmology cloud-based solutions at the AAO meeting in Chicago. Nextech and MDIntelleSys (MDI) unveiled a new, SaaS PM-EHR utilizing their com…

Read the full story
Load More

Advertisement

 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $22.64  1.62% 
 Akorn, Inc. $42.80  2.61% 
 Alimera Sciences, Inc. $5.38  11.85% 
 Allergan, Inc. $183.66  0.46% 
 Bayer $135.37  1.93% 
 Can-Fite Biopharma $3.05  0.43% 
 Carl Zeiss Meditec $21.04  0.45% 
 Cooper Companies, Inc. $156.13  0.92% 
 Escalon Medical Corp. $1.34  0.75% 
 Essilor International $105.00  0.00% 
 Imprimis Pharmaceuticals, Inc. $8.12  1.50% 
 InSite Vision, Inc. $0.28  -5.14% 
 IRIDEX Corporation $6.89  1.92% 
 Johnson & Johnson $102.59  1.35% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $48.94  1.79% 
 Merck & Company, Inc. $56.71  2.15% 
 NicOx $2.14  2.54% 
 NovaBay Pharmaceuticals, Inc. $0.74  -2.35% 
 Novartis AG Common Stock $89.32  1.28% 
 Ophthotech Corporation $39.75  1.09% 
 Quantel $3.31  0.30% 
 Roche $36.63  0.76% 
 STAAR Surgical Company $10.48  2.34% 
 TearLab Corporation $2.87  -1.37% 
 TLC Vision Corp $0.00  0.00% 
 Topcon Corporation $22.17  0.18% 
 Valeant Pharmaceuticals $128.38  -0.30%